Quinazolinones as γ-secretase modulators

Bioorganic and Medicinal Chemistry Letters

Volumn 21, Issue 2, 2011, Pages 773-776

  Fischer, Christian ^a   Shah, Sanjiv ^a   Hughes, Bethany L ^a   Nikov, George N ^a   Crispino, Jamie L ^a   Middleton, Richard E ^a   Szewczak, Alexander A ^a   Munoz, Benito ^a   Shearman, Mark S ^a  

^a Merck Research Laboratories Boston   (United States)

Author keywords

A 42 lowering; Alzheimer; APP; Gamma Secretase; Modulator

Indexed keywords

GAMMA SECRETASE INHIBITOR; QUINAZOLINONE DERIVATIVE;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; DRUG SYNTHESIS; ENZYME ACTIVITY; IC 50; NONHUMAN; RAT; STRUCTURE ACTIVITY RELATION;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AMYLOID PRECURSOR PROTEIN SECRETASES; ANIMALS; CELL LINE; HUMANS; INHIBITORY CONCENTRATION 50; PEPTIDE FRAGMENTS; PROTEIN BINDING; QUINAZOLINONES; RATS; RATS, SPRAGUE-DAWLEY;

EID: 78651252685     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2010.11.111     Document Type: Article

References (46)

1. Alzheimer's Association: 2009 Alzheimer's disease facts and figures http://www.alz.org/national/documents/report-alzfactsfigures.2009.pdf.
2. See for example: L.W. Hung, G.D. Ciccotosto, E. Giannakis, D.J. Tew, K. Perez, C.L. Masters, R. Cappai, J.D. Wade, and K.J. Barnham J. Neurosci. 28 2008 11950
3. H. Moreno, E. Yu, G. Pigino, A.I. Hernandez, N. Kim, J.E. Moreira, M. Sugimori, and R.R. Llinas Proc. Natl. Acad. Sci. 106 2009 5901
4. C-99 is the C-terminal fragment of the amyloid precursor protein (APP) produced by β-secretase mediated proteolysis of APP.
5. H. Li, M.S. Wolfe, and D.J. Selkoe Structure 17 2009 326
6. P. Osenkowski, H. Li, W. Ye, D. Li, L. Aeschbach, P.C. Fraering, M.S. Wolfe, D.J. Selkoe, and H. Li J. Mol. Biol. 385 2009 642
7. See for example: D.J. Selkoe, and M.S. Wolfe Cell 131 2007 215
8. M.S. Wolfe Curr. Top. Med. Chem. 8 2008 2
9. H. Steiner, R. Fluhrer, and C. Haass J. Biol. Chem. 283 2008 29627
10. M.S. Wolfe Semin. Cell Dev. Biol. 20 2009 219
11. For selected reviews, see: W.-L. Wu, and L. Zhang Drug Dev. Res. 70 2009 94
12. R.E. Olson, and C.F. Albright Curr. Top. Med. Chem. 8 2008 17
13. B.P. Imbimbo Drug Discovery Today 5 2008 169
14. For a recient reivew on APP processing, see: G. Thinakaran, and E.H. Koo J. Biol. Chem. 283 2008 29615
15. For a recent review on secretase biology and modes of γ-secretase inhibition/modulation, see: B. De Strooper, R. Vassar, and T. Golde Nat. Rev. Neurol. 6 2010 99
16. All GSMs lower Aβ42 selectively over Aβ40, however, some raise the levels of Aβ38 and/or Aβ37. The consequence of this difference is unknown.
17. For selected reviews on GSMs, see: I. Peretto, and E. La Porta Curr. Top. Med. Chem. 8 2008 38
18. D. Breher Curr. Top. Med. Chem. 8 2008 34
19. B.P. Imbimbo Curr. Top. Med. Chem. 8 2008 54
20. T. Tomita Expert Rev. Neurother. 9 2009 661
21. Flurizan is the cyclooxygenase (COX1 & 2)-inactive enantiomer of (S)-Flurbiprofen.
22. G. Evin Expert Rev. Neurother. 8 2008 1611
23. T.L. Kukar, T.B. Ladd, M.A. Bann, P.C. Fraering, R. Narlawar, G.M. Maharvi, B. Haely, R. Chapman, A.T. Welzel, R.W. Price, B. Moore, V. Rangachari, B. Cusack, J. Eriksen, K. Jansen-West, C. Verbeeck, D. Yager, C. Eckman, W. Ye, S. Sagi, B.A. Cottrell, J. Torpey, T.L. Rosenberry, A. Fauq, M.S. Wolfe, B. Schmidt, D.M. Walsh, E.H. Koo, and T.E. Golde Nature 453 2008 925
24. For patents in this area, see: Hannam, J. C.; Hartmann, S.; M., Andrew; R., Mark, P. WO2007110667.
25. Madin, A.; Ridgill, M. P.; Kulagowski, J. J. WO 2007116228.
26. Garcia, Y.; Hannam, J. C.; Harrison, T.; Hamblett, C. L.; Hubbs, J. L.; Kulagowski, J. J.; Madin, A.; Ridgill, M. P.; Seward, E. WO 2007125364.
27. Stanton, M. G.; Munoz, B.; Sloman, D. L.; Hubbs, J. L.; Hamblett, C. L. WO 2008030391.
28. Munoz, B.; Hubbs, J. L.; Hamblett, C. L.; Zhou, H.; Martinez, M. WO 2008085301.
29. For a recent publication, see: M.Z. Kounnas, A.M. Danks, S. Cheng, C. Tyree, E. Ackerman, X. Zhang, K. Ahn, P. Nguyen, D. Comer, L. Mao, C. Yu, D. Pleynet, P.J. Digregorio, G. Velicelebi, K.A. Stauderman, W.T. Comer, W.C. Mobley, Y.-M. Li, S.S. Sisodia, R.E. Tanzi, and S.L. Wagner Neuron 67 2010 769
30. For a key patent, see: Kimura, T.; Kawano, K.; Doi, E.; Kitazawa, N.; Shin, K.; Miyagawa, T.; Kaneko, T.; Ito, K.; Takaishi, M.; Sasaki, T.; Hagiwara, H. WO 2005115990.
31. Blurton, P.; Fletcher, S.; Teall, M.; Harrison, T.; Munoz, B.; Rivkin, A.; Hamblett, C.; Siliphaivanh, P.; Otte, K. WO 2008099210.
32. Rivkin, A.; Ahearn, S. P.; Chichetti, S. M.; Hamblett, C. L.; Garcia, Y.; Martinez, M.; Munoz, B. WO 2010019392.
33. A. Rivkin, S.P. Ahearn, S.M. Chichetti, Y.R. Kim, C. Li, A. Rosenau, S.D. Kattar, J. Jung, S. Shah, B.L. Hughes, J.L. Crispino, R.E. Middleton, A.A. Szewczak, B. Munoz, and M.S. Shearman Bioorg. Med. Chem. Lett. 20 2010 1269
34. A. Rivkin, S.P. Ahearn, S.M. Chichetti, C.L. Hamblett, Y. Garcia, M. Martinez, J.L. Hubbs, M.H. Reutershan, M.H. Daniels, P. Siliphaivanh, K.M. Otte, C. Li, A. Rosenau, L.M. Surdi, J. Jung, B.L. Hughes, J.L. Crispino, G.N. Nikov, R.E. Middleton, C.M. Moxham, A.A. Szewczak, S. Shah, L.Y. Moy, C.M. Kenific, F. Tanga, J.C. Cruz, P. Andrade, M.H. Angagaw, N.H. Shomer, T. Miller, B. Munoz, and M.S. Shearman Bioorg. Med. Chem. Lett. 20 2010 2279
35. Fischer, C.; Munoz, B.; Rivkin, A. WO 2008097538.
36. 50s >10 μM.
37. We have also investigated several other heterocyclic amide replacements, such as oxazoles, oxadiazoles, thiazoles and thiadiazoles. While all of them behaved as GSMs, their binding to the hERG channel was generally equal or greater than their cellular potency as GSMs.
38. Careful work-up and purification was necessary to remove the unwanted regio-isomer. See Ref. 18 for detailed synthetic procedures.
39. Other analogues, including amino quinazolines used in Table 2, were prepared in a similar manner. For detailed synthetic procedures, see Ref. 18
40. 50 measurements for inhibition of Aβ40 and Aβ42 production were determined using electrochemiluminescent detection of these peptides secreted by SH-SY5Y cells stably overexpressing the APP C-terminal fragment SPA4CT. Consistent with the profiles of γ-secretase modulators, total Aβ peptide levels were constant. The GSM profile of selected compounds was confirmed by mass spectrometry (SELDI), which confirmed the appearance of shorter (Aβ37) fragments while Aβ42 formation was suppressed. (a) Best, J. D.; Jay, M. T.; Otu, F.; Ma, J.; Nadin, A.; Ellis, S.; Lewis, H. D.; Pattison, C.; Reilly, M.; Harrison, T.; Shearman, M. S.; Williamson, T. L.; Atack, J. R. J. Pharmacol. Exp. Ther. 2005, 313, 902
41. (b) Clarke, E. E.; Shearman, M. S. J. Neurosci. Methods 2000, 102, 61;
42. (c) Dyrks, T.; Dyrks, E.; Monning, U.; Urmoneit, B.; Turner, J.; Beyreuther, K. FEBS Lett. 1993, 335, 89.
43. For a description of the hERG radioligand displacement assay, see: Butcher, J. W.; Claremon, D. A.; Connolly, T. M.; Dean, D. C.; Karczewski, J.; Koblan, K. S.; Kostura, M. J.; Liverton, N. J.; Melillo, D. G. WO 200205860.
44. Kr) currents with PatchXpress, compound 18 could not be fully evaluated due to solubility limitations; at the maximum soluble concentration (10 μM) a 39% (N = 4) mean blockade was observed.
45. Compound 31 was prepared in a one-pot procedure from the corresponding fused pyrimidone 24 according to: Z.-K. Wan, E. Binnun, D.P. Wilson, and J. Lee Org. Lett. 7 2005 5877
46. Solubility of compounds 15-24 was not quantifiable at pH 7 in phosphate buffered saline (PBS) buffer. Compounds 25 and 27 had 6 and 33 μM solubility, respectively, in PBS.